Brivaracetam UCB.
Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the potential treatment of neurological disorders, namely epilepsy and neuropathic pain. By December 2003, UCB reported that phase II epilepsy trials had begun [517569].
Malawska
Barbara
B
Jagiellonian University Medical College, Department of Physicochemical Drug Analysis, Medyczna 9, 30-688 Krakow, Poland. mfmalaws@cyf-kr.edu.pl
Kulig
Katarzyna
K
D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D015394:Molecular Structure; D009437:Neuralgia / Q000188:drug therapy; D011760:Pyrrolidinones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D000927:Anticonvulsants; D011760:Pyrrolidinones; C482793:brivaracetam